Antimicrobial resistance in the enterococcus

Bacterial Resistance to Antimicrobials, Second Edition

Volumn , Issue , 2007, Pages 255-289

  Eliopoulos, George M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867554637     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (262)

1. McDonald JR, Olaison L, Anderson DJ, et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 2005;118:759-66.
2. Storch GA and Krogstad DJ. Antibiotic-induced lysis of enterococci. J Clin Invest 1981;68:639-45.
3. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardio logy, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association:endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-434.
4. Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993;7:117-33.
5. Sader HS, Jones RN, Dowzicky MJ, and Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005;52:203-8.
6. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
7. Eliopoulos GM, Wennersten CB, Gold HS, et al. Characterization of vancomycinresistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother 1998;42:1088-92.
8. McNeil SA, Malani PN, Chenoweth CE, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis 2006;42:195-203.
9. Avery R, Kalaycio M, Pohlman B, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 2005;35:497-9.
10. Salgado CD and Farr BM. Outcomes associated with vancomycin-resistant enterococci:a meta-analysis. Infect Control Hosp Epidemiol 2003;24:690-8.
11. DiazGranados CA and Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005;191:588-95.
12. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006;12 Suppl 1:16-23.
13. Noble WC, Virani Z, and Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
14. Williamson R, le Bouguenec C, Gutmann L, and Horaud T. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 1985;131:1933-40.
15. al-Obeid S, Gutmann L, and Williamson R. Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci. J Antimicrob Chemother 1990;26:613-8.
16. Grayson ML, Eliopoulos GM, Wennersten CB, et al. Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillinbinding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother 1991;35:1408-12.
17. Fontana R, Cerini R, Longoni P, Grossato A, and Canepari P. Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin. J Bacteriol 1983;155:1343-50.
18. Piras G, el Kharroubi A, van Beeumen J, Coeme E, Coyette J, and Ghuysen JM. Characterization of an Enterococcus hirae penicillin-binding protein 3 with low penicillin affinity. J Bacteriol 1990;172:6856-62.
19. Eliopoulos GM, Wennersten CB, Gold HS, and Moellering RC, Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745-7.
20. Arbeloa A, Segal H, Hugonnet JE, et al. Role of class A penicillin-binding proteins in PBP5-mediated β-lactam resistance in Enterococcus faecalis. J Bacteriol 2004; 186:1221-8.
21. Comenge Y, Quintiliani R, Jr., Li L, et al. The CroRS two-component regulatory system is required for intrinsic β-lactam resistance in Enterococcus faecalis. J Bacteriol 2003;185:7184-92.
22. Muller C, Le Breton Y, Morin T, Benachour A, Auffray Y, and Rince A. The response regulator CroR modulates expression of the secreted stress-induced SalB protein in Enterococcus faecalis. J Bacteriol 2006;188:2636-45.
23. Cercenado E, Vicente MF, Diaz MD, Sanchez-Carrillo C, and Sanchez-Rubiales M. Characterization of clinical isolates of β-lactamase-negative, highly ampicillin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1996;40:2420-2.
24. Ono S, Muratani T, and Matsumoto T. Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother 2005;49:2954-8.
25. Metzidie E, Manolis EN, Pournaras S, Sofianou D, and Tsakris A. Spread of an unusual penicillin-and imipenem-resistant but ampicillin-susceptible phenotype among Enterococcus faecalis clinical isolates. J Antimicrob Chemother 2006;57:158-60.
26. Grayson ML, Eliopoulos GM, Wennersten CB, et al. Increasing resistance to β-lactam antibiotics among clinical isolates of Enterococcus faecium : a 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180-4.
27. Sifaoui F, Arthur M, Rice L, and Gutmann L. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob Agents Chemother 2001;45:2594-7.
28. Rice LB, Carias LL, Hutton-Thomas R, Sifaoui F, Gutmann L, and Rudin SD. Penicillin -binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 2001;45:1480-6.
29. Zorzi W, Zhou XY, Dardenne O, et al. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J Bacteriol 1996;178:4948-57.
30. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, and Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1994;38:1980-3.
31. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, and Gutmann L. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis 1998;178:159-63.
32. Ligozzi M, Pittaluga F, and Fontana R. Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1996;40:354-7.
33. Rice LB, Bellais S, Carias LL, et al. Impact of specific pbp5 mutations on expression of β-lactam resistance in Enterococcus faecium. Antimicrob Agents Chemother 2004;48:3028-32.
34. Rice LB, Carias LL, Rudin S, Lakticova V, Wood A, and Hutton-Thomas R. Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob Agents Chemother 2005;49:5007-12.
35. Carias LL, Rudin SD, Donskey CJ, and Rice LB. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 1998;180:4426-34.
36. Hanrahan J, Hoyen C, and Rice LB. Geographic distribution of a large mobile element that transfers ampicillin and vancomycin resistance between Enterococcus faecium strains. Antimicrob Agents Chemother 2000;44:1349-51.
37. Mainardi JL, Legrand R, Arthur M, Schoot B, van Heijenoort J, and Gutmann L. Novel mechanism of β-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J Biol Chem 2000;275:16490-6.
38. Mainardi JL, Morel V, Fourgeaud M, et al. Balance between two transpeptidation mechanisms determines the expression of β-lactam resistance in Enterococcus faecium. J Biol Chem 2002;277:35801-7.
39. Mainardi JL, Fourgeaud M, Hugonnet JE, et al. A novel peptidoglycan cross-linking enzyme for a β-lactam-resistant transpeptidation pathway. J Biol Chem 2005; 280:38146-52.
40. Biarrotte-Sorin S, Hugonnet JE, Delfosse V, et al. Crystal structure of a novel β-lactam-insensitive peptidoglycan transpeptidase. J Mol Biol 2006;359:533-8.
41. Murray BE and Mederski-Samaroj B. Transferable β-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168-71.
42. Murray BE, Church DA, Wanger A, et al. Comparison of two β-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother 1986;30:861-4.
43. Murray BE, Singh KV, Markowitz SM, et al. Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 1991;163:780-5.
44. Murray BE, Lopardo HA, Rubeglio EA, Frosolono M, and Singh KV. Intrahospital spread of a single gentamicin-resistant, β-lactamase-producing strain of Entero coccus faecalis in Argentina. Antimicrob Agents Chemother 1992;36:230-2.
45. Coudron PE, Markowitz SM, and Wong ES. Isolation of a β-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother 1992;36:1125-6.
46. McAlister T, George N, Faoagali J, and Bell J. Isolation of β-lactamase positive vancomycin resistant Enterococcus faecalis ; first case in Australia. Commun Dis Intell 1999;23:237-9.
47. Zhou JD, Guo JJ, Zhang Q, Chen Y, Zhu SH, and Peng HY. Drug resistance of infectious pathogens after liver transplantation. Hepatobiliary Pancreat Dis Int 2006;5:190-4.
48. Rhinehart E, Smith NE, Wennersten C, et al. Rapid dissemination of β-lactamaseproducing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med 1990;323:1814-8.
49. Markowitz SM, Wells VD, Williams DS, Stuart CG, Coudron PE, and Wong ES. Antimicrobial susceptibility and molecular epidemiology of β-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis. Antimicrob Agents Chemother 1991;35:1075-80.
50. Murray BE, Mederski-Samoraj B, Foster SK, Brunton JL, and Harford P. In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylo coccal origin. J Clin Invest 1986;77:289-93.
51. Murray BE, An FY, and Clewell DB. Plasmids and pheromone response of the β-lactamase producer Streptococcus (Enterococcus) faecalis HH22. Antimicrob Agents Chemother 1988;32:547-51.
52. Tomayko JF, Zscheck KK, Singh KV, and Murray BE. Comparison of the β-lactamase gene cluster in clonally distinct strains of Enterococcus faecalis. Antimicrob Agents Chemother 1996;40:1170-4.
53. Okamoto R, Okubo T, and Inoue M. Detection of genes regulating β-lactamase production in Enterococcus faecalis and Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:2550-4.
54. Rice LB, Eliopoulos GM, Wennersten C, Goldmann D, Jacoby GA, and Moellering RC, Jr. Chromosomally mediated β-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1991;35:272-6.
55. Rice LB and Carias LL. Transfer of Tn5385, a composite, multiresistance chromosomal element from Enterococcus faecalis. J Bacteriol 1998;180:714-21.
56. Nallapareddy SR, Wenxiang H, Weinstock GM, and Murray BE. Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J Bacteriol 2005;187:5709-18.
57. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, and Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
58. Draghi DC, Sheehan DJ, Hogan P, and Sahm DF. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024-32.
59. Fridkin SK, Yokoe DS, Whitney CG, Onderdonk A, and Hooper DC. Epidemiology of a dominant clonal strain of vancomycin-resistant Enterococcus faecium at separate hospitals in Boston, Massachusetts. J Clin Microbiol 1998;36:965-70.
60. Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821-8.
61. Hayden MK. Insights into the epidemiology and control of infection with vancomycinresistant enterococci. Clin Infect Dis 2000;31:1058-65.
62. Zirakzadeh A and Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006;81:529-36.
63. Martinez JA, Ruthazer R, Hansjosten K, Barefoot L, and Snydman DR. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905-12.
64. Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycinresistant Enterococcus faecium in long-term care patients and the significance of “clearance.” Clin Infect Dis 2001;33:1654-60.
65. Leclercq R. Enterococci acquire new kinds of resistance. Clin Infect Dis 1997;24 Suppl 1:S80-4.
66. Quintiliani R, Jr., Evers S, and Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis 1993; 167:1220-3.
67. Hayden MK, Trenholme GM, Schultz JE, and Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J Infect Dis 1993; 167:1224-7.
68. Dutka-Malen S, Blaimont B, Wauters G, and Courvalin P. Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus. Antimicrob Agents Chemother 1994;38:1675-7.
69. Liassine N, Frei R, Jan I, and Auckenthaler R. Characterization of glycopeptideresistant enterococci from a Swiss hospital. J Clin Microbiol 1998;36:1853-8.
70. Poulsen RL, Pallesen LV, Frimodt-Moller N, and Espersen F. Detection of clinical vancomycin-resistant enterococci in Denmark by multiplex PCR and sandwich hybridization. Apmis 1999;107:404-12.
71. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis 2006;42 Suppl 1:S25-34.
72. Leclercq R, Derlot E, Duval J, and Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157-61.
73. Leclercq R and Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-54.
74. Lester CH, Frimodt-Moller N, Sorensen TL, Monnet DL, and Hammerum AM. In vivo transfer of the vanA resistance gene from an Enterococcus faecium isolate of animal origin to an E. faecium isolate of human origin in the intestines of human volunteers. Antimicrob Agents Chemother 2006;50:596-9.
75. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, and Walsh CT. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 1991;30:10408-15.
76. Reynolds PE, Depardieu F, Dutka-Malen S, Arthur M, and Courvalin P. Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine. Mol Microbiol 1994;13:1065-70.
77. Wu Z, Wright GD, and Walsh CT. Overexpression, purification, and characterization of VanX, a D-, D-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 1995;34:2455-63.
78. Arthur M, Depardieu F, Gerbaud G, Galimand M, Leclercq R, and Courvalin P. The VanS sensor negatively controls VanR-mediated transcriptional activation of glycopeptide resistance genes of Tn1546 and related elements in the absence of induction. J Bacteriol 1997;179:97-106.
79. Arthur M, Depardieu F, Reynolds P, and Courvalin P. Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol Microbiol 1996;21:33-44.
80. Holman TR, Wu Z, Wanner BL, and Walsh CT. Identification of the DNA-binding site for the phosphorylated VanR protein required for vancomycin resistance in Enterococcus faecium. Biochemistry 1994;33:4625-31.
81. Haldimann A, Fisher SL, Daniels LL, Walsh CT, and Wanner BL. Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12. J Bacteriol 1997;179:5903-13.
82. Arthur M, Depardieu F, Snaith HA, Reynolds PE, and Courvalin P. Contribution of VanY D, D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob Agents Chemother 1994; 38:1899-903.
83. Arthur M, Depardieu F, Molinas C, Reynolds P, and Courvalin P. The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin. Gene 1995;154:87-92.
84. Pootoolal J, Thomas MG, Marshall CG, et al. Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from Streptomyces toyocaensis NRRL15009. Proc Natl Acad Sci USA 2002;99:8962-7.
85. Patel R. Enterococcal-type glycopeptide resistance genes in non-enterococcal organisms. FEMS Microbiol Lett 2000;185:1-7.
86. Patel R, Piper K, Cockerill FR, 3rd, Steckelberg JM, and Yousten AA. The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrob Agents Chemother 2000;44:705-9.
87. Fraimow H, Knob C, Herrero IA, and Patel R. Putative VanRS-like two-component regulatory system associated with the inducible glycopeptide resistance cluster of Paenibacillus popilliae. Antimicrob Agents Chemother 2005;49:2625-33.
88. Guardabassi L, Christensen H, Hasman H, and Dalsgaard A. Members of the genera Paenibacillus and Rhodococcus harbor genes homologous to enterococcal glycopeptide resistance genes vanA and vanB. Antimicrob Agents Chemother 2004;48:4915-8.
89. Guardabassi L, Perichon B, van Heijenoort J, Blanot D, and Courvalin P. Glycopeptide resistance vanA operons in Paenibacillus strains isolated from soil. Antimicrob Agents Chemother 2005;49:4227-33.
90. Dahl KH, Simonsen GS, Olsvik O, and Sundsfjord A. Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:1105-10.
91. Evers S, Courvalin P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J Bacteriol 1996;178:1302-9.
92. Baptista M, Depardieu F, Courvalin P, and Arthur M. Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis. Antimicrob Agents Chemother 1996;40:2291-5.
93. Baptista M, Rodrigues P, Depardieu F, Courvalin P, and Arthur M. Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of a VanBtype Enterococcus faecalis. Mol Microbiol 1999;32:17-28.
94. Quintiliani R, Jr., Courvalin P. Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol Lett 1994;119:359-63.
95. Quintiliani R, Jr. and Courvalin P. Characterization of Tn1547, a composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM4281. Gene 1996;172:1-8.
96. Lu JJ, Chang TY, Perng CL, and Lee SY. The vanB2 gene cluster of the majority of vancomycin-resistant Enterococcus faecium isolates from Taiwan is associated with the pbp5 gene and is carried by Tn5382 containing a novel insertion sequence. Antimicrob Agents Chemother 2005;49:3937-9.
97. Stinear TP, Olden DC, Johnson PD, Davies JK, and Grayson ML. Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet 2001;357:855-6.
98. Ballard SA, Pertile KK, Lim M, Johnson PD, and Grayson ML. Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother 2005;49:1688-94.
99. Launay A, Ballard SA, Johnson PD, Grayson ML, and Lambert T. Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother 2006;50:1054-62.
100. Patel R, Uhl JR, Kohner P, Hopkins MK, and Cockerill FR, 3rd. Multiplex PCR detection of vanA, vanB, vanC-1, and vanC-2/3 genes in enterococci. J Clin Microbiol 1997; 35:703-7.
101. Reynolds PE and Courvalin P. Vancomycin resistance in enterococci due to synthesis of precursors terminating in D-alanyl-D-serine. Antimicrob Agents Chemother 2005; 49:21-5.
102. Reynolds PE, Snaith HA, Maguire AJ, Dutka-Malen S, and Courvalin P. Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. Biochem J 1994;301 (Pt 1):5-8.
103. Arias CA, Martin-Martinez M, Blundell TL, Arthur M, Courvalin P, and Reynolds PE. Characterization and modelling of VanT: a novel, membrane-bound, serine racemase from vancomycin-resistant Enterococcus gallinarum BM4174. Mol Microbiol 1999; 31:1653-64.
104. Ambur OH, Reynolds PE, and Arias CA. D-Ala:D-Ala ligase gene flanking the vanC cluster: evidence for presence of three ligase genes in vancomycin-resistant Enterococcus gallinarum BM4174. Antimicrob Agents Chemother 2002;46:95-100.
105. Reynolds PE, Arias CA, and Courvalin P. Gene vanXYC encodes D, D-dipeptidase (VanX) and D, D-carboxypeptidase (VanY) activities in vancomycin-resistant Enterococcus gallinarum BM4174. Mol Microbiol 1999;34:341-9.
106. Panesso D, Abadia-Patino L, Vanegas N, Reynolds PE, Courvalin P, and Arias CA. Transcriptional analysis of the vanC cluster from Enterococcus gallinarum strains with constitutive and inducible vancomycin resistance. Antimicrob Agents Chemother 2005;49:1060-6.
107. Corso A, Faccone D, Gagetti P, et al. First report of VanA Enterococcus gallinarum dissemination within an intensive care unit in Argentina. Int J Antimicrob Agents 2005;25:51-6.
108. Camargo IL, Barth AL, Pilger K, Seligman BG, Machado AR, and Darini AL. Enterococcus gallinarum carrying the vanA gene cluster: first report in Brazil. Braz J Med Biol Res 2004;37:1669-71.
109. Mammina C, Di Noto AM, Costa A, and Nastasi A. VanB-VanC1 Enterococcus gallinarum, Italy. Emerg Infect Dis 2005;11:1491-2.
110. Schooneveldt JM, Marriott RK, and Nimmo GR. Detection of a vanB determinant in Enterococcus gallinarum in Australia. J Clin Microbiol 2000;38:3902.
111. Iaria C, Stassi G, Costa GB, Di Leo R, Toscano A, and Cascio A. Enterococcal meningitis caused by Enterococcus casseliflavus. First case report. BMC Infect Dis 2005;5:3.
112. Takayama Y, Sunakawa K, and Akahoshi T. Meningitis caused by Enterococcus gallinarum in patients with ventriculoperitoneal shunts. J Infect Chemother 2003; 9:348-50.
113. Choi SH, Lee SO, Kim TH, et al. Clinical features and outcomes of bacteremia caused by Enterococcus casseliflavus and Enterococcus gallinarum: analysis of 56 cases. Clin Infect Dis 2004;38:53-61.
114. Toye B, Shymanski J, Bobrowska M, Woods W, and Ramotar K. Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype). J Clin Microbiol 1997;35:3166-70.
115. Dargere S, Vergnaud M, Verdon R, et al. Enterococcus gallinarum endocarditis occurring on native heart valves. J Clin Microbiol 2002;40:2308-10.
116. Depardieu F, Perichon B, and Courvalin P. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J Clin Microbiol 2004;42:5857-60.
117. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 2001;7:229-36.
118. Perichon B, Reynolds P, and Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997;41:2016-8.
119. Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C, et al. A cluster of VanD vancomycinresistant Enterococcus faecium: molecular characterization and clinical epidemiology. J Infect Dis 1999;180:1177-85.
120. Depardieu F, Kolbert M, Pruul H, Bell J, and Courvalin P. VanD-type vancomycinresistant Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2004;48:3892-904.
121. Boyd DA, Miller MA, and Mulvey MR. Enterococcus gallinarum N04-0414 harbors a VanD-type vancomycin resistance operon and does not contain a D-alanine:D-alanine 2 (ddl2) gene. Antimicrob Agents Chemother 2006;50:1067-70.
122. Reynolds PE, Ambur OH, Casadewall B, and Courvalin P. The VanY(D) DD-carboxypeptidase of Enterococcus faecium BM4339 is a penicillin-binding protein. Microbiology 2001;147:2571-8.
123. Fines M, Perichon B, Reynolds P, Sahm DF, and Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999;43:2161-4.
124. Abadia Patino L, Courvalin P, and Perichon B. vanE gene cluster of vancomycinresistant Enterococcus faecalis BM4405. J Bacteriol 2002;184:6457-64.
125. Abadia-Patino L, Christiansen K, Bell J, Courvalin P, and Perichon B. vanE -type vancomycin-resistant Enterococcus faecalis clinical isolates from Australia. Antimicrob Agents Chemother 2004;48:4882-5.
126. McKessar SJ, Berry AM, Bell JM, Turnidge JD, and Paton JC. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000;44:3224-8.
127. Depardieu F, Bonora MG, Reynolds PE, and Courvalin P. The vanG glycopeptide resistance operon from Enterococcus faecalis revisited. Mol Microbiol 2003;50:931-48.
128. Cremniter J, Mainardi JL, Josseaume N, et al. Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium. J Biol Chem 2006;281:32254-62.
129. Steenbergen JN, Alder J, Thorne GM, and Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-8.
130. Critchley IA, Blosser-Middleton RS, Jones ME, Thornsberry C, Sahm DF, and Karlowsky JA. Baseline study to determine in vitro activities of daptomycin against Gram-positive pathogens isolated in the United States in 2000-2001. Antimicrob Agents Chemother 2003;47:1689-93.
131. Munoz-Price LS, Lolans K, and Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 2005;41:565-6.
132. Lewis JS, 2nd, Owens A, Cadena J, Sabol K, Patterson JE, and Jorgensen JH. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005;49:1664-5.
133. Friedman L, Alder JD, and Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:2137-45.
134. Geraci JE and Martin WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954;10:173-94.
135. Moellering RC, Jr. and Weinberg AN. Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest 1971;50:2580-4.
136. Vakulenko SB and Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003;16:430-50.
137. Eliopoulos GM, Farber BF, Murray BE, Wennersten C, and Moellering RC, Jr. Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother 1984;25:398-9.
138. Clark NC, Olsvik O, Swenson JM, Spiegel CA, and Tenover FC. Detection of a streptomycin/spectinomycin adenylyltransferase gene aadA. Antimicrob Agents Chemother 1999;43:157-60.
139. Krogstad DJ, Korfhagen TR, Moellering RC, Jr., Wennersten C, and Swartz MN. Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest 1978; 62:480-6.
140. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000;31:586-9.
141. Chen YG, Qu TT, Yu YS, Zhou JY, and Li LJ. Insertion sequence ISEcp1-like element connected with a novel aph(2 ') allele [aph(2')-Ie] conferring high-level gentamicin resistance and a novel streptomycin adenylyltransferase gene in Enterococcus. J Med Microbiol 2006;55:1521-5.
142. Moellering RC, Jr., Korzeniowski OM, Sande MA, and Wennersten CB. Speciesspecific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis 1979;140:203-8.
143. Calderwood SB, Wennersten C, and Moellering RC, Jr. Resistance to antibiotic synergism in Streptococcus faecalis : further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin. Antimicrob Agents Chemother 1981;19:549-55.
144. Thauvin C, Eliopoulos GM, Wennersten C, and Moellering RC, Jr. Antagonistic effect of penicillin-amikacin combinations against enterococci. Antimicrob Agents Chemother 1985;28:78-83.
145. Mahbub Alam M, Kobayashi N, Ishino M, et al. Detection of a novel aph(2 ') allele [aph(2')-Ie] conferring high-level gentamicin resistance and a spectinomycin resistance gene ant(9)-Ia (aad 9) in clinical isolates of enterococci. Microb Drug Resist 2005;11:239-47.
146. Carlier C and Courvalin P. Emergence of 4',4'-aminoglycoside nucleotidyltransferase in enterococci. Antimicrob Agents Chemother 1990;34:1565-9.
147. Costa Y, Galimand M, Leclercq R, Duval J, and Courvalin P. Characterization of the chromosomal aac(6 ')-Ii gene specific for Enterococcus faecium. Antimicrob Agents Chemother 1993;37:1896-903.
148. Del Campo R, Galan JC, Tenorio C, et al. New aac(6 ')-I genes in Enterococcus hirae and Enterococcus durans: effect on (β)-lactam/aminoglycoside synergy. J Anti microb Chemother 2005;55:1053-5.
149. Horodniceanu T, Bougueleret L, El-Solh N, Bieth G, and Delbos F. High-level, plasmidborne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes. Antimicrob Agents Chemother 1979;16:686-9.
150. Eliopoulos GM. Antibiotic resistance in Enterococcus species: an update. Curr Clin Top Infect Dis 1996;16:21-51.
151. Eliopoulos GM, Wennersten C, Zighelboim-Daum S, Reiszner E, Goldmann D, and Moellering RC, Jr. High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother 1988;32:1528-32.
152. Ferretti JJ, Gilmore KS, and Courvalin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2'-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J Bacteriol 1986;167:631-8.
153. Daigle DM, Hughes DW, and Wright GD. Prodigious substrate specificity of AAC(6')-APH(2'), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci. Chem Biol 1999;6:99-110.
154. Straut M, de Cespedes G, and Horaud T. Plasmid-borne high-level resistance to gentamicin in Enterococcus hirae, Enterococcus avium, and Enterococcus raffinosus. Antimicrob Agents Chemother 1996;40:1263-5.
155. Donabedian SM, Thal LA, Hershberger E, et al. Molecular characterization of gentamicin-resistant Enterococci in the United States: evidence of spread from animals to humans through food. J Clin Microbiol 2003;41:1109-13.
156. Hodel-Christian SL and Murray BE. Characterization of the gentamicin resistance transposon Tn5281 from Enterococcus faecalis and comparison to staphylococcal transposons Tn4001 and Tn4031. Antimicrob Agents Chemother 1991;35:1147-52.
157. Thal LA, Chow JW, Clewell DB, and Zervos MJ. Tn924, a chromosome-borne transposon encoding high-level gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1994;38:1152-6.
158. Rice LB, Carias LL, and Marshall SH. Tn5384, a composite enterococcal mobile element conferring resistance to erythromycin and gentamicin whose ends are directly repeated copies of IS256. Antimicrob Agents Chemother 1995;39:1147-53.
159. Patterson JE, Masecar BL, Kauffman CA, Schaberg DR, Hierholzer WJ, Jr., and Zervos MJ. Gentamicin resistance plasmids of enterococci from diverse geographic areas are heterogeneous. J Infect Dis 1988;158:212-6.
160. Casetta A, Hoi AB, de Cespedes G, and Horaud T. Diversity of structures carrying the high-level gentamicin resistance gene (aac6-aph2) in Enterococcus faecalis strains isolated in France. Antimicrob Agents Chemother 1998;42:2889-92.
161. Kao SJ, You I, Clewell DB, et al. Detection of the high-level aminoglycoside resistance gene aph(2 ')-Ib in Enterococcus faecium. Antimicrob Agents Chemother 2000; 44:2876-9.
162. Chow JW, Kak V, You I, et al. Aminoglycoside resistance genes aph(2 ')-Ib and aac(6')-Im detected together in strains of both Escherichia coli and Enterococcus faecium. Antimicrob Agents Chemother 2001;45:2691-4.
163. Chow JW, Zervos MJ, Lerner SA, et al. A novel gentamicin resistance gene in Enterococcus. Antimicrob Agents Chemother 1997;41:511-4.
164. Chow JW, Donabedian SM, Clewell DB, Sahm DF, and Zervos MJ. In vitro susceptibility and molecular analysis of gentamicin-resistant enterococci. Diagn Microbiol Infect Dis 1998;32:141-6.
165. Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, and Chow JW. A new high-level gentamicin resistance gene, aph(2 ')-Id, in Enterococcus spp. Antimicrob Agents Chemother 1998;42:1229-32.
166. Vakulenko SB, Donabedian SM, Voskresenskiy AM, Zervos MJ, Lerner SA, and Chow JW. Multiplex PCR for detection of aminoglycoside resistance genes in enterococci. Antimicrob Agents Chemother 2003;47:1423-6.
167. Moellering RC, Jr., Murray BE, Schoenbaum SC, Adler J, and Wennersten CB. A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis. J Infect Dis 1980;141:81-6.
168. Aslangul E, Ruimy R, Chau F, Garry L, Andremont A, and Fantin B. Relationship between the level of acquired resistance to gentamicin and synergism with amoxicillin in Enterococcus faecalis. Antimicrob Agents Chemother 2005;49:4144-8.
169. Aslangul E, Massias L, Meulemans A, et al. Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis. Antimicrob Agents Chemother 2006; 50:3615-21.
170. Schulin T, Wennersten CB, Moellering RC, Jr., and Eliopoulos GM. In vitro activity of RU 64004, a new ketolide antibiotic, against Gram-positive bacteria. Antimicrob Agents Chemother 1997;41:1196-202.
171. Schmitz FJ, Verhoef J, and Fluit AC. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group. J Antimicrob Chemother 1999; 43:783-92.
172. Jones RN, Sader HS, Erwin ME, and Anderson SC. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis 1995;21:85-93.
173. Atkinson BA, Abu-Al-Jaibat A, and LeBlanc DJ. Antibiotic resistance among enterococci isolated from clinical specimens between 1953 and 1954. Antimicrob Agents Chemother 1997;41:1598-600.
174. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, and Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999;43:2823-30.
175. Shaw JH and Clewell DB. Complete nucleotide sequence of macrolide-lincosamidestreptogramin B-resistance transposon Tn917 in Streptococcus faecalis. J Bacteriol 1985;164:782-96.
176. Leclercq R and Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-72.
177. Pepper K, Horaud T, Le Bouguenec C, and de Cespedes G. Location of antibiotic resistance markers in clinical isolates of Enterococcus faecalis with similar antibiotypes. Antimicrob Agents Chemother 1987;31:1394-402.
178. Bonafede ME, Carias LL, and Rice LB. Enterococcal transposon Tn5384 : evolution of a composite transposon through cointegration of enterococcal and staphylococcal plasmids. Antimicrob Agents Chemother 1997;41:1854-8.
179. Portillo A, Ruiz-Larrea F, Zarazaga M, Alonso A, Martinez JL, and Torres C. Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother 2000; 44:967-71.
180. Rosato A, Vicarini H, and Leclercq R. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J Antimicrob Chemother 1999;43:559-62.
181. Oh TG, Kwon AR, and Choi EC. Induction of ermAMR from a clinical strain of Enterococcus faecalis by 16-membered-ring macrolide antibiotics. J Bacteriol 1998; 180:5788-91.
182. Luna VA, Coates P, Eady EA, Cove JH, Nguyen TT, and Roberts MC. A variety of Gram-positive bacteria carry mobile mef genes. J Antimicrob Chemother 1999; 44:19-25.
183. Singh KV, Malathum K, and Murray BE. Disruption of an Enterococcus faecium species-specific gene, a homologue of acquired macrolide resistance genes of staphylococci, is associated with an increase in macrolide susceptibility. Antimicrob Agents Chemother 2001;45:263-6.
184. Werner G, Hildebrandt B, and Witte W. The newly described msrC gene is not equally distributed among all isolates of Enterococcus faecium. Antimicrob Agents Chemother 2001;45:3672-3.
185. Aakra A, Vebo H, Snipen L, et al. Transcriptional response of Enterococcus faecalis V583 to erythromycin. Antimicrob Agents Chemother 2005;49:2246-59.
186. Singh KV and Murray BE. Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin. Antimicrob Agents Chemother 2005;49:32-9.
187. Dassa E and Bouige P. The ABC of ABCS: a phylogenetic and functional classification of ABC systems in living organisms. Res Microbiol 2001;152:211-29.
188. Malathum K, Coque TM, Singh KV, and Murray BE. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria. Antimicrob Agents Chemother 1999;43:930-6.
189. Lim JA, Kwon AR, Kim SK, Chong Y, Lee K, and Choi EC. Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital. J Antimicrob Chemother 2002;49:489-95.
190. Singh KV, Weinstock GM, and Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristindalfopristin. Antimicrob Agents Chemother 2002;46:1845-50.
191. Dina J, Malbruny B, and Leclercq R. Nonsense mutations in the lsa -like gene in Enterococcus faecalis isolates susceptible to lincosamides and Streptogramins A. Antimicrob Agents Chemother 2003;47:2307-9.
192. Bozdogan B, Berrezouga L, Kuo MS, et al. A new resistance gene, linB, conferring resistance to lincosamides by nucleotidylation in Enterococcus faecium HM1025. Antimicrob Agents Chemother 1999;43:925-9.
193. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81.
194. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, and Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437-51.
195. Rende-Fournier R, Leclercq R, Galimand M, Duval J, and Courvalin P. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother 1993;37:2119-25.
196. Hammerum AM, Jensen LB, and Aarestrup FM. Detection of the satA gene and transferability of virginiamycin resistance in Enterococcus faecium from food-animals. FEMS Microbiol Lett 1998;168:145-51.
197. Werner G, Klare I, and Witte W. Association between quinupristin/dalfopristin resistance in glycopeptide-resistant Enterococcus faecium and the use of additives in animal feed. Eur J Clin Microbiol Infect Dis 1998;17:401-2.
198. Werner G and Witte W. Characterization of a new enterococcal gene, satG, encoding a putative acetyltransferase conferring resistance to Streptogramin A compounds. Antimicrob Agents Chemother 1999;43:1813-4.
199. Soltani M, Beighton D, Philpott-Howard J, and Woodford N. Mechanisms of resistance to quinupristin-dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in Western Europe. Antimicrob Agents Chemother 2000;44:433-6.
200. Donabedian SM, Perri MB, Vager D, et al. Quinupristin-dalfopristin resistance in Enterococcus faecium isolates from humans, farm animals, and grocery store meat in the United States. J Clin Microbiol 2006;44:3361-5.
201. Allignet J and El Solh N. Characterization of a new staphylococcal gene, vgaB, encoding a putative ABC transporter conferring resistance to streptogramin A and related compounds. Gene 1997;202:133-8.
202. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F, and Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999;43:1062-6.
203. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, and Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006;50:2500-5.
204. Jensen LB, Hammerum AM, Aerestrup FM, van den Bogaard AE, and Stobberingh EE. Occurrence of satA and vgb genes in streptogramin-resistant Enterococcus faecium isolates of animal and human origins in the Netherlands. Antimicrob Agents Chemother 1998;42:3330-1.
205. Bozdogan B and Leclercq R. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium. Antimicrob Agents Chemother 1999;43:2720-5.
206. Bozdogan B, Leclercq R, Lozniewski A, and Weber M. Plasmid-mediated coresistance to streptogramins and vancomycin in Enterococcus faecium HM1032. Antimicrob Agents Chemother 1999;43:2097-8.
207. Barriere JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, and Desnottes JF. Recent developments in streptogramin research. Curr Pharm Des 1998;4:155-80.
208. Caron F, Gold HS, Wennersten CB, Farris MG, Moellering RC, Jr., and Eliopoulos GM. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1997;41:2749-53.
209. Jones RN, Farrell DJ, and Morrissey I. Quinupristin-dalfopristin resistance in Streptococcus pneumoniae : novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2003;47:2696-8.
210. Malbruny B, Canu A, Bozdogan B, et al. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus. Antimicrob Agents Chemother 2002;46:2200-7.
211. Lautenbach E, Schuster MG, Bilker WB, and Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259-65.
212. Norris AH, Reilly JP, Edelstein PH, Brennan PJ, and Schuster MG. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 1995;20:1137-44.
213. Scapellato PG, Ormazabal C, Scapellato JL, and Bottaro EG. Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol. J Clin Microbiol 2005;43:3578-9.
214. Perez Mato S, Robinson S, and Begue RE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol. Pediatr Infect Dis J 1999; 18:483-4.
215. Ricaurte JC, Boucher HW, Turett GS, Moellering RC, Labombardi VJ, and Kislak JW. Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect 2001;7:17-21.
216. Mutnick AH, Biedenbach DJ, and Jones RN. Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2003;46:63-8.
217. Gould CV, Fishman NO, Nachamkin I, and Lautenbach E. Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infect Control Hosp Epidemiol 2004;25:138-45.
218. Courvalin PM, Shaw WV, and Jacob AE. Plasmid-mediated mechanisms of resistance to aminoglycoside-aminocyclitol antibiotics and to chloramphenicol in group D streptococci. Antimicrob Agents Chemother 1978;13:716-25.
219. Trieu-Cuot P, de Cespedes G, Bentorcha F, Delbos F, Gaspar E, and Horaud T. Study of heterogeneity of chloramphenicol acetyltransferase (CAT) genes in streptococci and enterococci by polymerase chain reaction: characterization of a new CAT determinant. Antimicrob Agents Chemother 1993;37:2593-8.
220. Lynch C, Courvalin P, and Nikaido H. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 1997;41:869-71.
221. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, and Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-6.
222. Flannagan SE, Zitzow LA, Su YA, and Clewell DB. Nucleotide sequence of the 18-kb conjugative transposon Tn916 from Enterococcus faecalis. Plasmid 1994; 32:350-4.
223. Franke AE and Clewell DB. Evidence for a chromosome-borne resistance transposon (Tn916) in Streptococcus faecalis that is capable of “conjugal” transfer in the absence of a conjugative plasmid. J Bacteriol 1981;145:494-502.
224. Nishimoto Y, Kobayashi N, Alam MM, Ishino M, Uehara N, and Watanabe N. Analysis of the prevalence of tetracycline resistance genes in clinical isolates of Enterococcus faecalis and Enterococcus faecium in a Japanese hospital. Microb Drug Resist 2005; 11:146-53.
225. Charpentier E, Gerbaud G, and Courvalin P. Presence of the Listeria tetracycline resistance gene tet(S) in Enterococcus faecalis. Antimicrob Agents Chemother 1994;38:2330-5.
226. Roberts AP, Davis IJ, Seville L, Villedieu A, and Mullany P. Characterization of the ends and target site of a novel tetracycline resistance-encoding conjugative transposon from Enterococcus faecium 664.1H1. J Bacteriol 2006;188:4356-61.
227. McMurry LM, Park BH, Burdett V, and Levy SB. Energy-dependent efflux mediated by class L (TetL) tetracycline resistance determinant from streptococci. Antimicrob Agents Chemother 1987;31:1648-50.
228. Bentorcha F, De Cespedes G, and Horaud T. Tetracycline resistance heterogeneity in Enterococcus faecium. Antimicrob Agents Chemother 1991;35:808-12.
229. Boucher HW, Wennersten CB, and Eliopoulos GM. In vitro activities of the glycyl cycline GAR-936 against Gram-positive bacteria. Antimicrob Agents Chemother 2000;44:2225-9.
230. Jones RN, Ross JE, Fritsche TR, and Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006;57:279-87.
231. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, and Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52:215-27.
232. Streit JM, Sader HS, Fritsche TR, and Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 2005;53:307-10.
233. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005;51:291-5.
234. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, and Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
235. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, and Quinn JP. Risk factors associated with the development of infection with linezolid-and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269-72.
236. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, and Quinn JP. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis : evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003;47:511-3.
237. Dobbs TE, Patel M, Waites KB, Moser SA, Stamm AM, and Hoesley CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006;44:3368-70.
238. Herrero IA, Issa NC, and Patel R. Nosocomial spread of linezolid-resistant, vancomycin -resistant Enterococcus faecium. N Engl J Med 2002;346:867-9.
239. Bonora MG, Ligozzi M, Luzzani A, Solbiati M, Stepan E, and Fontana R. Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment. Eur J Clin Microbiol Infect Dis 2006;25:197-8.
240. Meka VG, and Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010-5.
241. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001;45:2154-6.
242. Johnson AP, Tysall L, Stockdale MV, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002;21:751-4.
243. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, and Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002;46:3334-6.
244. Jones RN, Della-Latta P, Lee LV, and Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2002; 42:137-9.
245. Dibo I, Pillai SK, Gold HS, et al. Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient. J Clin Microbiol 2004;42:1843-5.
246. Klare I, Konstabel C, Mueller-Bertling S, et al. Spread of ampicillin/vancomycinresistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Infect Dis 2005; 24:815-25.
247. Bae HG, Sung H, Kim MN, Lee EJ and Koo Lee S. First report of a linezolid-and vancomycin-resistant Enterococcus faecium strain in Korea. Scand J Infect Dis 2006;38:383-6.
248. Lobritz M, Hutton-Thomas R, Marshall S, and Rice LB. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob Agents Chemother 2003;47:3318-20.
249. Woodford N, Tysall L, Auckland C, et al. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 2002;40:4298-300.
250. Sinclair A, Arnold C, and Woodford N. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci. Antimicrob Agents Chemother 2003;47:3620-2.
251. Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, and Sommers HM. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrob Agents Chemother 1984;25:633-7.
252. Tankovic J, Mahjoubi F, Courvalin P, Duval J, and Leclerco R. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 1996;40:2558-61.
253. Eliopoulos GM. Activity of newer fluoroquinolones in vitro against Gram-positive bacteria. Drugs 1999;58 Suppl 2:23-8.
254. Korten V, Huang WM, and Murray BE. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1994;38:2091-4.
255. Kanematsu E, Deguchi T, Yasuda M, Kawamura T, Nishino Y, and Kawada Y. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1998;42:433-5.
256. el Amin NA, Jalal S, and Wretlind B. Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother 1999;43:947-9.
257. Jonas BM, Murray BE, and Weinstock GM. Characterization of emeA, a NorA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob Agents Chemother 2001;45:3574-9.
258. Lee EW, Huda MN, Kuroda T, Mizushima T, and Tsuchiya T. EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis. Antimicrob Agents Chemother 2003; 47:3733-8.
259. Oyamada Y, Ito H, Fujimoto K, et al. Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol 2006;55:729-36.
260. Oyamada Y, Ito H, Inoue M, and Yamagishi J. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis. J Med Microbiol 2006;55:1395-401.
261. Davis DR, McAlpine JB, Pazoles CJ, et al. Enterococcus faecalis multi-drug resistance transporters: application for antibiotic discovery. J Mol Microbiol Biotechnol 2001; 3:179-84.
262. Paulsen IT, Banerjei L, Myers GS, et al. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 2003;299:2071-4.